Mode
Text Size
Log in / Sign up
N/A N=1,053 Randomized Single-blind Prevention

Evaluations of Alcohol Warning Labels

Oral Cancer · Esophageal Cancer · Larynx Cancer · Alcohol Drinking

Enrolled (actual)
1,053
Serious AEs
Results posted
Nov 2025
Primary outcome: Primary: Dwell Time — 8.75; 8.47 seconds

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Narrative pictorial warning labels for alcoholic beverages (Behavioral); Non-narrative pictorial warning labels for alcoholic beverages (Behavioral)
Age
Adult, Older Adult · 21+ yrs
Sex
All
Sponsor
University of Connecticut
Primary completion
Mar 2024

Outcome Measures

OutcomeResultp-value
PRIMARY
Dwell Time
8.75; 8.47
PRIMARY
Visit Count
13.74; 13.58
PRIMARY
Reactance
2.38; 2.54
PRIMARY
Affective Risk Perceptions
2.27; 2.38
PRIMARY
Experiential Risk Perceptions
2.35; 2.46
PRIMARY
Perceived Susceptibility
2.072; 2.102
PRIMARY
Comparative Risk
2.71; 2.85
PRIMARY
Perceived Severity of Harm
4.47; 4.55
PRIMARY
Intentions to Reduce Drinking
3.08; 3.14
PRIMARY
Intentions to Stop Drinking
2.26; 2.37 0.256

Summary

The goal of this study is to determine the effectiveness of pictorial warning labels (PWLs) featuring narrative (vs. non-narrative) content in communicating the cancer risk of alcohol. Participants will be randomized to view either three narrative or non-narrative PWLs. Key outcome variables include visual attention, message reactance, risk perceptions, and intentions to reduce and stop drinking.

Eligibility Criteria

Inclusion Criteria

  • be at least 21 years old;
  • have consumed more than three alcoholic drinks per week over the past year;
  • be willing to participate in remote eye tracking tasks and have necessary technical support to complete remote eye tracking tasks (i.e., having access to high-speed Internet and a computer/tablet/phone equipped with a high-speed camera).

Exclusion Criteria

  • be younger than 21 years old;
  • has not consumed more than three alcoholic drinks per week over the past year;
  • be not willing to participate in remote eye tracking tasks and have no necessary technical support to complete remote eye tracking tasks (i.e., having access to high-speed Internet and a computer/tablet/phone equipped with a high-speed camera).
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT06129487). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search